Explore Dentsply's (XRAY) international revenue trends and how these numbers impact Wall Street's forecasts and what's ahead for the stock.
DENTSPLY SIRONA Inc. (NASDAQ:XRAY ) Q4 2024 Earnings Conference Call February 27, 2025 8:30 AM ET Company Participants Andrea Daley - Vice President of Investor Relations Simon Campion - President & Chief Executive Officer Herman Cueto - Interim Chief Financial Officer Conference Call Participants Elizabeth Anderson - Evercore ISI Erin Wright - Morgan Stanley Brandon Vazquez - William Blair David Saxon - Needham & Company Jeffrey Johnson - Baird Kevin Caliendo - UBS Michael Cherny - Leerink Partners Jonathan Block - Stifel Jason Bednar - Piper Sandler Operator Good day and thank you for standing by. Welcome to the Q4 2024 DENTSPLY SIRONA Earnings Conference Call.
DENTSPLY SIRONA's fourth-quarter results showcase dismal segmental performance with declining adjusted operating income.
Dentsply International (XRAY) came out with quarterly earnings of $0.26 per share, missing the Zacks Consensus Estimate of $0.43 per share. This compares to earnings of $0.44 per share a year ago.
Evaluate the expected performance of Dentsply (XRAY) for the quarter ended December 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
XRAY is likely to have faced a tough fourth quarter with Byte's revenue loss, weak U.S. equipment demand and implant pressures.
Dentsply (XRAY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
NEW YORK, NY / ACCESSWIRE / January 15, 2025 / If you suffered a loss on your Dentsply Sirona Inc. (NASDAQ:XRAY) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: Click Here or contact Joseph E. Levi, Esq.
NEW YORK, NY / ACCESSWIRE / January 15, 2025 / WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Dentsply Sirona Inc. (NASDAQ:XRAY) between May 6, 2021 and November 6, 2024, both dates inclusive (the "Class Period"), of theimportant January 27, 2025 lead plaintiff deadline. SO WHAT: If you purchased Dentsply Sirona common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
NEW YORK, NY / ACCESSWIRE / January 15, 2025 / If you suffered a loss on your Dentsply Sirona Inc. (NASDAQ:XRAY) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: Click Here or contact Joseph E. Levi, Esq.
NEW YORK, NY / ACCESSWIRE / January 15, 2025 / If you suffered a loss on your Dentsply Sirona Inc. (NASDAQ:XRAY) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: Click Here or contact Joseph E. Levi, Esq.
NEW YORK, NY / ACCESSWIRE / January 15, 2025 / If you suffered a loss on your Dentsply Sirona Inc. (NASDAQ:XRAY) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: Click Here or contact Joseph E. Levi, Esq.